MedTrace Logo

A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

NCT02240459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2020-02-19

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Conditions

Interventions

DRUG

fesoterodine 4mg

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

DRUG

Oxybutynin

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

DRUG

placebo

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

DRUG

fesoterodine 8mg

2, 4mg fesoterodine capsules taken together in the morning

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Alberta

    lead OTHER

Principal Investigators

  • Adrian S Wagg, MD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02240459 on ClinicalTrials.gov